Biomarker update for breast, colorectal and non-small cell lung cancer

Drug News and Perspectives

Volumn 23, Issue 1, 2010, Pages 82-88

  Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CETUXIMAB; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RISK; CANCER THERAPY; COLORECTAL CANCER; DISEASE MARKER; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; ONCOGENE NEU; PREDICTOR VARIABLE; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 77950606791     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.1.1437316     Document Type: Review

References (63)

1. Wasielewski, R., Hasselmann, S., Rüschoff, J., Fisseler-Eckhoff, A., Kreipe, H. Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch 2008, 453(6): 537-543
2. Yaziji H., Taylor, CR., Goldstein, N.S. et al. Members of the Standardization Ad-Hoc Consensus Committee. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol 2008, 16(6): 513-520
3. Gown, A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008, 21(Suppl. 2): S8-S15.
4. Jordan, V.C., Brodie, A.M. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007, 72(1): 7-25.
5. Diaz, L.K., Sneige, N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 2005, 12(1): 10-19
6. Wolff, A.C, Hammond, M.E., Schwartz, J.N. et al. American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131(1): 18-43.
7. Harvey, J.M., Clark, CM., Osborne, C.K., Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17(5): 1474-1481
8. Ross, J.S. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical out-come. Adv Anat Pathol 2009, 16(4): 204-215
9. Ross, J.S., Slodkowska, E.A., Symmans, W.F., Pusztai, L., Ravdin, P.M., Hortobagyi, CN. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14(4): 320-368
10. Lewis Phillips, G.D., Li, G, Dugger, D.L et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008, 68(22): 9280-90.
11. Tokuda, Y., Suzuki, Y., Saito, Y, Umemura, S. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: An updated review. Breast Cancer 2009, 16(4): 295-300.
12. Penault-Llorca, F, Bilous, M., Dowsett, M., Hanna, W., Osamura, R.Y, Rüschoff, J., van de Vijver, M. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol 2009, 132(4): 539-548
13. Toi, M., Sperinde, J., Huang, W. et al. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinicbased cohort of patients with metastatic breast cancer. J Clin Oncol 2007, 25(18S): 1025.
14. Pestrin, M., Bessi, S., Galardi, F. et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009, 118(3): 523-530
15. Cianfrocca, M., Gradishar, W. New molecular classifications of breast cancer. CA Cancer J Clin 2009, 59(5): 303-313
16. Cuadros, M., Villegas, R. Systematic review of HER2 breast cancer testing. Appl lmmunohistochem Mol Morphol 2009, 17(1): 1-7.
17. Walker, R.A., Bartlett, J.M., Dowsett, M. et al. HER2 testing in the UK: Further update to recommendations. J Clin Pathol 2008 61(7): 818-824
18. Lyman, G.H., Cosier, L.E., Kuderer, N.M., Hornberger, J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer 2007, 109(6): 1011-1018
19. Knoop, A.S., Knudsen, H., Batslev, E. et al. Danish Breast Cancer Cooperative Group. Retrospective analysis of topoisomerose IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005, 23(30): 7483-7490
20. Ross, J.S., Slodkowska, E.A. Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol 2009, 132(2): 237-245
21. Amadori, A., Rossi, E., Zamarchi, R., Carli, P., Pastorelli, D., Jirillo, A. Circulating and disseminated tumor cells in the clinical management of breast cancer patients: Unanswered questions. Oncology 2009, 76(6): 375-386
22. Sequist, L.V., Nagrath, S., Toner, M., Haber, D.A., Lynch, T.J. The CTC-chip: An exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 2009, 4(3): 281-283
23. Tsouma, A., Aggeli, C., Pissimissis, N., Lembessis, P., Zografos, G.N., Koutsilleris, M. Circulating tumor cells in colorectal cancer: Detection methods and clinical significance. Anticancer Res 2008, 28(6B): 3945-3960
24. Riethdorf, S., Wikman, H., Pantel, K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008, 123(9): 1991-2006.
25. Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., Bardelli, A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009, 101(19): 1308-1324
26. Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M. et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal anti-bodies in colorectal cancer. PLoS One 2009, 4(10): e7287.
27. Monzon, F.A., Ogino, S., Hammond, M.E., Hailing, KC, Bloom, K.J., Nikiforova, M.N. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009, 133(10): 1600-1606
28. Plesec, T.P., Hunt, J.L. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009, 16(4): 196-203.
29. Jimeno, A., Messersmith, W.A., Hirsch, F.R., Franklin, W.A., Eckhardt, S.G. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: Practical application of patient selection. J Clin Oncol 2009, 27(7): 1130-1136
30. Loupakis, F, Ruzzo, A., Cremolini, C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101(4): 715-721
31. Di Nicolantonio, F., Martini, M., Molinari, F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35): 5705-5712
32. Sartore-Bianchi, A., Martini, M., Molinari, F. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-tar-geted monoclonal antibodies. Cancer Res 2009, 69(5): 1851-1857
33. Jhawer, M., Goel, S., Wilson, AJ. et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008, 68(6): 1953-1961
34. Oden-Gangloff, A., Di Fiore, F, Bibeau, F. et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer 2009, 100(8): 1330-1335
35. Laurent-Puig, P., Cayre, A., Manceau, G. et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27(35): 5924-5930
36. Lenz, HJ. Pharmacogenomics and colorectal cancer. Adv Exp Med Biol 2006, 587: 211-231
37. Ahmed, FE. Molecular markers that predict response to colon cancer therapy. Expert Rev Mol Diagn 2005, 5(3): 353-375
38. Palomaki, G.E., Bradley, L.A., Douglas, M.P., Kolor, K., Dotson, W.D. Con UGTlA1 genotyp-ing reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009, 11(1): 21-34.
39. Deeken, J.F., Slack, R., Marshall, J.L. Irinotecan and uridine diphosphate glucurono-syltransferase 1A1 pharmacogenetics: To test or not to test, that is the question. Cancer 2008, 113(7): 1502-1510
40. Nagar, S., Blanchard, R.L. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 2006, 38(3): 393-409.
41. Van Cutsem, E., Kang, Y, Chung, H. et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. J Clin Oncol 2009, 27(18S): Abst LBA4509.
42. Hirsch, FR., Varella-Garcia, M., Dziadziuszko R. et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res 2008, 14(19): 6317-6323
43. Pérez-Soler, R. Individualized therapy in non-small-cell lung cancer: Future versus current clinical practice. Oncogene 2009, 28(Suppl. 1): S38-45.
44. John, T., Liu, G., Tsao, M.S. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, pro-tein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl. 1): S14-23.
45. Linardou, H., Dahabreh, I.J., Bafaloukos, D., Kosmidis, P., Murray, S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009, 6(6): 352-366
46. Gazdar, A.F Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl. 1): S24-31.
47. Pennell, N.A., Lynch, TJ. Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009, 14(4): 399-411.
48. Azzoli, CC, Baker, S. Jr., Temin, S. et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27(36): 6251-6266
49. Massarelli, E., Varella-Garcia, M., Tang, X. et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13(10): 2890-2896
50. Bonomi, P.D., Buckingham, L., Coon, J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 2007, 13(15 Pt. 2): S4606-12.
51. Herbst, R.S., Prager D., Hermann R. et al. TRIBUTE Investigator Group. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(25): 5892-5899
52. Olaussen, K.A., Fouret, P., Kroemer, G. ERCC1-specific immunostaining in non-small-cell lung cancer. N Engl J Med 2007, 357(15): 1559-1561
53. Vilmar, A., Sørensen, J.B. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carbo-platin: A review of current literature. Lung Cancer 2009, 64(2): 131-139
54. Breen, D., Barlési, F. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. Eur J Cardiothorac Surg 2008, 33(5): 805-811
55. Olaussen, K.A., Mountzios, G, Soria, J.C. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 2007,13(4): 284-289
56. Felip, E., Rosell, R. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn 2007,7(3): 261-268
57. Kalikaki, A., Kanaki, M., Vassalou, H., Souglakos, J., Voutsina, A., Georgoulias, V., Mavroudis, D. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009, 10(2): 118-123
58. Takenaka, T., Yano, T., Kiyohara, C. et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide poly-morphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2009, 67(1): 101-107
59. Ikeda, N., Nagase, S., Ohira, T Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers. Ann Thorac Cardiovasc Surg 2009, 15(3): 144-149
60. Schettino, C., Bareschino, M.A., Maione, P., Rossi, A., Ciardiello, F., Gridelli, C. The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. Curr Genomics 2008, 9(4): 252-262
61. Singh, N., Aggarwal, A.N. ERCC1 and RRM1 expression in nonsmall cell lung cancer - The good, the bad and the unknown. J Thorac Oncol 2009, 4(8): 1042-1043
62. Toffalorio, F, Giovannetti, E., De Pas, T. et al. Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. Pharmacogenomics J 2009, Advanced publication.
63. Tiseo, M., Bartolotti, M., Gelsomino, F, Ardizzoni, A. First-line treatment in advanced non-small-cell lung cancer: The emerging role of the histologic subtype. Expert Rev Anticancer Ther 2009, 9(4): 425-435